Krystal Biotech Q4 EPS $0.30 Beats $(0.39) Estimate, Sales $42.14M Beat $28.61M Estimate
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech reported Q4 earnings of $0.30 per share, surpassing the $(0.39) estimate, marking a 124% increase from last year's $(1.25) per share loss. Q4 sales reached $42.14M, exceeding the $28.61M estimate by 47.30%.
February 26, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's Q4 earnings and sales significantly exceeded analyst estimates, with earnings per share at $0.30 against a $(0.39) estimate and sales of $42.14M against a $28.61M estimate.
The significant beat on both earnings per share and sales estimates for Krystal Biotech indicates a strong financial performance and operational efficiency. This outperformance, especially the shift from a loss to a profit compared to the same period last year, is likely to instill investor confidence and could lead to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100